Outcome following resection for patients with primary mediastinal nonseminomatous germ-cell tumors and rising serum tumor markers post-chemotherapy

S. M. Radaideh, V. C. Cook, Kenneth Kesler, Lawrence Einhorn

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: To assess the outcome of surgical resection in patients with primary mediastinal nonseminomatous germ-cell tumors (PMNSGCT) with rising serum tumor markers (STM) following standard platinum-based chemotherapy. Patients and methods: A total of 158 consecutive patients with PMNSGCT who received platinum-based chemotherapy followed by complete surgical extirpation of residual disease at Indiana University from 1982 to 2007 were retrospectively reviewed. Thirty-five of these 158 patients had rising STM at time of resection. Results: Thirty-five patients (34 males and 1 female) comprise the basis of this report. Three patients had rising human chorionic gonadotropin, and the remaining 32 patients had rising alpha-fetoprotein at the time of thoracic surgery. Twenty-four of the 35 (69%) pathologically demonstrated viable germ-cell tumor, while 8 patients had teratoma and 3 patients had necrosis only at time of resection, despite the presence of rising STM. Twenty-seven patients normalized their tumor markers postoperatively. Twenty-one of 35 died, 5 were lost to follow-up, and 9 are alive. Of the nine patients alive, seven are continuously disease free with median follow-up of 64 months (range 25-220 months). Conclusion: The presence of rising STM doesn't preclude successful therapy with surgical resection, especially if carried out by experienced thoracic surgical oncologists.

Original languageEnglish
Pages (from-to)804-807
Number of pages4
JournalAnnals of Oncology
Volume21
Issue number4
DOIs
StatePublished - Nov 4 2009

Fingerprint

Tumor Biomarkers
Biomarkers
Drug Therapy
Platinum
Nonseminomatous germ cell tumor
Germ Cell and Embryonal Neoplasms
Lost to Follow-Up
Teratoma
alpha-Fetoproteins
Chorionic Gonadotropin
Thoracic Surgery
Necrosis
Thorax

Keywords

  • Outcome
  • Primary mediastinal nonseminomatous germ-cell tumors
  • Resection
  • Surgery
  • Tumor markers

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

@article{4e23831d9faa4d9fb16cc151b9977b25,
title = "Outcome following resection for patients with primary mediastinal nonseminomatous germ-cell tumors and rising serum tumor markers post-chemotherapy",
abstract = "Background: To assess the outcome of surgical resection in patients with primary mediastinal nonseminomatous germ-cell tumors (PMNSGCT) with rising serum tumor markers (STM) following standard platinum-based chemotherapy. Patients and methods: A total of 158 consecutive patients with PMNSGCT who received platinum-based chemotherapy followed by complete surgical extirpation of residual disease at Indiana University from 1982 to 2007 were retrospectively reviewed. Thirty-five of these 158 patients had rising STM at time of resection. Results: Thirty-five patients (34 males and 1 female) comprise the basis of this report. Three patients had rising human chorionic gonadotropin, and the remaining 32 patients had rising alpha-fetoprotein at the time of thoracic surgery. Twenty-four of the 35 (69{\%}) pathologically demonstrated viable germ-cell tumor, while 8 patients had teratoma and 3 patients had necrosis only at time of resection, despite the presence of rising STM. Twenty-seven patients normalized their tumor markers postoperatively. Twenty-one of 35 died, 5 were lost to follow-up, and 9 are alive. Of the nine patients alive, seven are continuously disease free with median follow-up of 64 months (range 25-220 months). Conclusion: The presence of rising STM doesn't preclude successful therapy with surgical resection, especially if carried out by experienced thoracic surgical oncologists.",
keywords = "Outcome, Primary mediastinal nonseminomatous germ-cell tumors, Resection, Surgery, Tumor markers",
author = "Radaideh, {S. M.} and Cook, {V. C.} and Kenneth Kesler and Lawrence Einhorn",
year = "2009",
month = "11",
day = "4",
doi = "10.1093/annonc/mdp516",
language = "English",
volume = "21",
pages = "804--807",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Outcome following resection for patients with primary mediastinal nonseminomatous germ-cell tumors and rising serum tumor markers post-chemotherapy

AU - Radaideh, S. M.

AU - Cook, V. C.

AU - Kesler, Kenneth

AU - Einhorn, Lawrence

PY - 2009/11/4

Y1 - 2009/11/4

N2 - Background: To assess the outcome of surgical resection in patients with primary mediastinal nonseminomatous germ-cell tumors (PMNSGCT) with rising serum tumor markers (STM) following standard platinum-based chemotherapy. Patients and methods: A total of 158 consecutive patients with PMNSGCT who received platinum-based chemotherapy followed by complete surgical extirpation of residual disease at Indiana University from 1982 to 2007 were retrospectively reviewed. Thirty-five of these 158 patients had rising STM at time of resection. Results: Thirty-five patients (34 males and 1 female) comprise the basis of this report. Three patients had rising human chorionic gonadotropin, and the remaining 32 patients had rising alpha-fetoprotein at the time of thoracic surgery. Twenty-four of the 35 (69%) pathologically demonstrated viable germ-cell tumor, while 8 patients had teratoma and 3 patients had necrosis only at time of resection, despite the presence of rising STM. Twenty-seven patients normalized their tumor markers postoperatively. Twenty-one of 35 died, 5 were lost to follow-up, and 9 are alive. Of the nine patients alive, seven are continuously disease free with median follow-up of 64 months (range 25-220 months). Conclusion: The presence of rising STM doesn't preclude successful therapy with surgical resection, especially if carried out by experienced thoracic surgical oncologists.

AB - Background: To assess the outcome of surgical resection in patients with primary mediastinal nonseminomatous germ-cell tumors (PMNSGCT) with rising serum tumor markers (STM) following standard platinum-based chemotherapy. Patients and methods: A total of 158 consecutive patients with PMNSGCT who received platinum-based chemotherapy followed by complete surgical extirpation of residual disease at Indiana University from 1982 to 2007 were retrospectively reviewed. Thirty-five of these 158 patients had rising STM at time of resection. Results: Thirty-five patients (34 males and 1 female) comprise the basis of this report. Three patients had rising human chorionic gonadotropin, and the remaining 32 patients had rising alpha-fetoprotein at the time of thoracic surgery. Twenty-four of the 35 (69%) pathologically demonstrated viable germ-cell tumor, while 8 patients had teratoma and 3 patients had necrosis only at time of resection, despite the presence of rising STM. Twenty-seven patients normalized their tumor markers postoperatively. Twenty-one of 35 died, 5 were lost to follow-up, and 9 are alive. Of the nine patients alive, seven are continuously disease free with median follow-up of 64 months (range 25-220 months). Conclusion: The presence of rising STM doesn't preclude successful therapy with surgical resection, especially if carried out by experienced thoracic surgical oncologists.

KW - Outcome

KW - Primary mediastinal nonseminomatous germ-cell tumors

KW - Resection

KW - Surgery

KW - Tumor markers

UR - http://www.scopus.com/inward/record.url?scp=77951968577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951968577&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdp516

DO - 10.1093/annonc/mdp516

M3 - Article

C2 - 19889611

AN - SCOPUS:77951968577

VL - 21

SP - 804

EP - 807

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 4

ER -